Avita Medical, Inc. Common Stock (RCEL) Stock
Key stats
- Market cap
- $543.57M
- Price / Earnings ratio
- -15.4x
- EPS (TTM)
- -$1.17
- Volume
- Loading
- 52-week high
- $18.43
- 52-week low
- $3.22
Source: third-party data provider, as of November 13, 2026
Compare with RCEL
Recent news
All You Need to Know About Avita Medical (RCEL) Rating Upgrade to Buy
All You Need to Know About Avita Medical (RCEL) Rating Upgrade to Buy
RCEL
Avita Medical Inc. (RCEL) is a Great Momentum Stock: Should You Buy?
Avita Medical Inc. (RCEL) is a Great Momentum Stock: Should You Buy?
RCEL
Avita Medical PermeaDerm Study Shows 70% Cost Reduction vs. Allograft
Avita Medical PermeaDerm Study Shows 70% Cost Reduction vs. Allograft
RCEL
Avita Medical Raises 2026 Revenue Outlook as Q2 Sales Climb 18%
Avita Medical Raises 2026 Revenue Outlook as Q2 Sales Climb 18%
RCELTechnical indicators
- RSI 14
- 68.01
- MACD 12/26/9
- 1.17
- EMA 9 of MACD
- 1.12
- MACD histogram
- 0.05
- SMA 50
- $13.20
- Price above SMA 50
- EMA 50
- $13.43
- Price above EMA 50
- SMA 200
- $7.05
- Price above SMA 200
- EMA 200
- $8.15
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 3 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news
All You Need to Know About Avita Medical (RCEL) Rating Upgrade to Buy
All You Need to Know About Avita Medical (RCEL) Rating Upgrade to Buy
RCELAvita Medical Inc. (RCEL) is a Great Momentum Stock: Should You Buy?
Avita Medical Inc. (RCEL) is a Great Momentum Stock: Should You Buy?
RCELAvita Medical PermeaDerm Study Shows 70% Cost Reduction vs. Allograft
Avita Medical PermeaDerm Study Shows 70% Cost Reduction vs. Allograft
RCELAvita Medical Raises 2026 Revenue Outlook as Q2 Sales Climb 18%
Avita Medical Raises 2026 Revenue Outlook as Q2 Sales Climb 18%
RCEL
Avita Medical Targets Q4 2025 Cash Flow Breakeven as Revenue Growth Builds
Avita Medical Targets Q4 2025 Cash Flow Breakeven as Revenue Growth Builds
RCEL
Here Are Thursday's Top Wall Street Analyst Research Calls: AON, Apollo Global Managment, Bullish, Jack Henry, Marsh & McClennan, Nasdaq, NVIDIA,
Here Are Thursday's Top Wall Street Analyst Research Calls: AON, Apollo Global Managment, Bullish, Jack Henry, Marsh & McClennan, Nasdaq, NVIDIA,
RCELAbout Avita Medical, Inc. Common Stock
Avita is largely a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently used in most of the 140 US burn centers. Despite having product approval in Australia, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region, although international sales, particularly in Japan, are growing. Avita is domiciled, and has its primary listing, in the US.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Cary G. Vance | President, CEO & Executive Director | 1966 |
| Mr. David O'Toole | Chief Financial Officer | 1959 |
| Ms. Nicole Linda Kelsey | Chief Legal & Compliance Officer & Corporate Secretary | 1967 |
| Dr. Niraj Doshi J.D., P.M.P., Ph.D. | Senior Vice President of Global Operations | — |
| Dr. Katie Bush Ph.D. | Senior Vice President of Scientific & Medical Affairs | — |
| Mr. Ben Atkins | Vice President of Investor Relations & Corporate Communications | — |
| Ms. Debbie Garner | Senior Vice President of Global Marketing & Strategy | — |
| Mr. Rob Jones | Senior Vice President of Human Resources | — |
| Mr. Ron Lagerquist | Senior Vice President of Quality Assurance & Regulatory Affairs | — |
| Ms. Robin VanDenburgh | Senior Vice President of U.S. Commercial Sales | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 68.01
- MACD 12/26/9
- 1.17
- EMA 9 of MACD
- 1.12
- MACD histogram
- 0.05
- SMA 50
- $13.20
- Price above SMA 50
- EMA 50
- $13.43
- Price above EMA 50
- SMA 200
- $7.05
- Price above SMA 200
- EMA 200
- $8.15
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
3 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $14.00
- Average
- $18.33
- High
- $21.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +118.1 | +16.5 | +30.3 | +12.3 |
